Histological examination revealed no obvious side effects with 5‐mg/kg Anti‐PIEZO1‐MMAE treatment in the heart, liver, spleen, lung, kidney, skin, intestine, and stomach (Figure 5D), suggesting that Anti‐PIEZO1‐MMAE is a safe and specific drug candidate against ESCC for future investigation (Figure 6). Here, PIEZO1 is linked to esophageal squamous cell carcinoma.